secwatch.observer — SEC 8-K summary
======================================

Issuer:     SpringWorks Therapeutics, Inc. (—)
CIK:        0001773427
Form:       8-K
Filed at:   2024-05-17T23:59:59+00:00
Accession:  0001104659-24-063076
Event type: other
Sentiment:  neutral
Materiality: 0.10
Item codes: 5.07
LLM model:  deepseek-v4-flash:cloud@v2

SpringWorks stockholders re-elect Freda Lewis-Hall as director, ratify EY, approve say-on-pay
--------------------------------------------------------------------------------

- Freda Lewis-Hall elected Class II director: 50.3M for, 15.8M withheld, 3.4M abstentions.
- Ratification of Ernst & Young as FY2024 auditor: 69.5M for, 5,709 against, 10,294 abstentions.
- Non-binding advisory vote on executive compensation approved: 38.3M for, 27.8M against, 3.4M abstentions.
- All three proposals passed at May 16, 2024 annual meeting.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1773427/000110465924063076/0001104659-24-063076-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1773427/000110465924063076/tm2414870d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-24-063076

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer